

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office
1-703-872-9306
on 10 October 2002.



Signature

Kerri Pollard Schray

Typed or printed name of person signing Certificate

FAX RECEIVED

OCT 11 2002

GROUP 1600

OFFICIAL

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Amendment Transmittal
Response to Restriction Requirement
Change of Attorney Docket Number

(1 page—in duplicate)
(1 page)
(1 page)

Total (Including this Transmittal)

Pages (5 pages)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Practitioner's Docket No. MPI97-018CP1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Moore, Karen J., et al

Application No.: 09/724392

Group No.: 1646

Filed: November 28, 2000

Examiner: J.F. Murphy

For: NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Amendment Transmittal (1 page) (in duplicate);
 - b. Response to Restriction Requirement (1 page); and
 - c. Change of Attorney Docket No. (1 page).

STATUS

2. Applicant is other than a small entity.

FEE DEFICIENCY

3. It is believed no fees are due in connection with this submission, however, if any extension and/or fee is required, please charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

10 October 2002

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray

Registration No. 47.066

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-551-3676

Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature Date: 10 October 2002Kerri Pollard Schray

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)